ROIV
NASDAQ
$34.96
Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive business model that leverages cutting-edge technologies. The company has developed a promising pipeline addressing critical unmet medical needs in neurology, immunology, and rare diseases, which positions it well to streamline the drug development process while managing costs effectively. With a leadership team rich in industry experience and a network of strategic partnerships, Roivant is poised to drive financial growth and improve patient outcomes, making it an attractive investment opportunity for institutional investors.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $39.32 (+12.47%)
Market Cap
$25B
Free Cash Flow Yield
-3.06%
Beta (5Y)
0.90
Price Chart
Valuation
Market Cap$25B
P/S3008.13
P/B5.55
Profitability
Total Revenue (TTM)$8.26M
Gross Profit (TTM)-$674M
EBITDA-$512M
Operating Margin-14675%
EPS-$0.45
Financial Health
Free Cash Flow Yield-3.06%
Growth & Risk
Revenue 5Y CAGR-19.07%
FCF 5Y CAGR+6.34%
Beta (5Y)0.90
Sharpe Ratio2.68